Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2/3 1

Status

Recruiting 8Active not recruiting 5Not yet recruiting 1

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 8

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 2

Conditions

Lymphoma, Follicular 4Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Recruiting × Bendamustine Hydrochloride × 30 days × Clear all
NCT06284122 2026-06-05

MorningLyte

The Lymphoma Academic Research Organisation

Phase 3 Recruiting
790 enrolled
Lymphoid

Lymphoma, Follicular

NCT05139017 2026-06-04

waveLINE-003

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06084936 2026-06-03

GLOBRYTE

Hoffmann-La Roche

Phase 3 Recruiting
182 enrolled
Lymphoid

Lymphoma

NCT07139873 2026-06-03

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Dizal Pharmaceuticals

Phase 3 Recruiting
250 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06191744 2026-06-02

EPCOREâ„¢FL-2

Genmab

Phase 3 Recruiting
1,095 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06846671 2026-05-29

CaDAnCe-302

BeOne Medicines

Phase 3 Recruiting
250 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Celgene

Phase 3 Recruiting
400 enrolled
Lymphoid

Lymphoma, Follicular

NCT06091254 2026-05-19

OLYMPIA-1

Regeneron Pharmaceuticals

Phase 3 Recruiting
822 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡